Rimonabant, a brand new fat-loss medication to be sold as Acomplia, has just been approved by the EU and is currently available to patients in the UK.. The UK is, the very first region that Acomplia will be marketed, however it is likely to be a number of years before the medication is available to the general public.

Tests of Rimonabant more than the last few years have shown it to be an efficient fat-loss aid for some patients. It was found that, of those taking 20mg tablets of Rimonabant, a third lost more than 10 percent of their starting body fat, whilst more than 60 percent lost more than 5 percent. Average waist measurements are seen to have lowerd by between 6 and 9 cm (3-4 inches).

Rimonabant is the anorectic anti-obesity, CB1 Cannabinoid receptor antagonist medication. The most vital key of its effect is diminution in desiring food. Developed by Sanofi-Aventis, Acomplia (generic rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endogenous cannabinoids, such as anadamide, increases appetite.

Sanofi worked on the idea that if cannabinoids promote hunger cravings, blocking cannabinoid receptors in the brain might lower cravings. The main cannabinoid (CB1) receptors are believed to play a role in controlling food intake. To develop appropriate medications against this target, the human cannabinoid receptor was first cloned and then put into in cells.

The main idea consists in blocking the CB1 receptor, a part of Endocannabinoid System (EC System). This way Rimonabant stabilizes the more than-activation of the EC system and you won’t suffer from strong hunger. It is not an issue if you miss a dose of this medication as you may take it at any time. However you shouldn’t take two doses together. The medication should be stored at the room (roughly 25 C) temperature, avoiding sunlight. Be sure that children can’t get it.